Suven Life Sciences, a Hyderabad based company has presented data of investigational neuroscience compounds at Neuroscience 2005 meeting held at Washington DC, USA. Neuroscience is the annual meeting of the Society for Neuroscience (SFN).

Suven has presented new data for 4 promising areas of neuroscience viz. Alzheimer’s, Schizophrenia, Parkinson and Obesity diseases. These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programs in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients, a company release stated.

Suven’s presentation at SFN discussed about effect of selective 5-HT6 receptor antagonists on food-intake and body weight gain, SUVN-501, a potent and selective 5-HT6-receptor antagonist reverses scopolamine-induced amnesia in Morris water maze, SUVN-502: pharmacological profile of SUVN-502: A potent and selective 5-HT6-receptor antagonist, effect of selective 5-HT6 receptor antagonists SUVN-501, and SUVN-502 in rodent model of working memory and effect of selective 5-HT6 receptor antagonists in rodent models of learning.

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven’s CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005. A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven’s commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas.

Suven has R&D strength of more than 170 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front-end project management services from New Jersey, USA.